

Print this Page

Close Window

Chinese Scientist Fanyi Zeng to Present at World Stem Cell Summit on iPS Cells Producing Viable Mice

Posted on : 2009-07-23 | Author : Genetics Policy Institute
News Category : PressRelease

WASHINGTON - (Business Wire) Fanyi Zeng, PhD., MD., of the Institute of Medical Genetics, Shanghai Jiao Tong University, a principal investigator in a new paper published in the scientific journal *Nature* this week, will present her work at the upcoming 2009 World Stem Cell Summit. Dr. Zeng will participate on the science panel "Human Embryonic Stem Cells versus Induced Pluripotent Cells."

"We congratulate Fanyi Zeng and her colleague Qi Zhou on their achievement, which clearly demonstrates the versatility of reprogrammed cells in mice. Their research has broad applications and will place us further along the path to understanding the earliest stage of development and the root causes of disease. The work of Dr. Zeng is of keen interest to the global stem cell community and the general public. We are delighted to showcase her groundbreaking work at the World Stem Cell Summit," Bernard Siegel, co-chair of the World Stem Cell Summit, said.

The 2009 World Stem Cell Summit will take place on September 21-23 at the Baltimore Convention Center, Baltimore, Maryland, USA.

Presented by the Genetics Policy Institute (GPI), www.genpol.org, the 2009 Summit is hosted by Johns Hopkins University, the University System of Maryland, University of Maryland-Baltimore, Maryland Department of Business & Economic Development, Maryland Technology Development Corporation and Maryland Stem Cell Research Fund.

With more than 150 supporting organizations and media partners, the World Stem Cell Summit is the flagship, networking event, bringing together the visionary researchers, clinicians, business pathfinders, policy-makers, regulators, advocates, experts in law and ethics to present compelling presentations, share information, and together chart the future of regenerative medicine.

The comprehensive, multi-track program covers all areas of stem cell science (embryonic, adult and iPS), disease progress reports, drug discovery, tissue engineering, scaffolds, bioreactors and nanotechnology. Panels cover commercialization, funding, economic development, Federal agencies' perspectives, biobanking and ethics.

The Summit will attract 1,200 of the most influential stem cell stakeholders from 25 countries representing the fields of science, business, policy, law, ethics

